Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927055 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
A Phase 3 study, sponsored by Chelsea Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT01927055 is a Phase 3 study that was terminated before completion, run by Chelsea Therapeutics. The registered enrollment target is 61 participants.
The verdict
NCT01927055, a Phase 3 study, was terminated before completion, sponsored by Chelsea Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
Interventions
- DRUG Placebo
- DRUG Droxidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927055
The ClinicalTrials.gov registry entry for NCT01927055 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chelsea Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01927055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927055 about?
NCT01927055 is a clinical study titled "A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy". Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
What is the current status of trial NCT01927055?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2013-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01927055?
The interventions under investigation include: Placebo (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT01927055?
This trial is sponsored by Chelsea Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.